Although it was the first mover in getting a chimeric antigen receptor T-cell (CAR-T) therapy approved, Novartis AG has somewhat fallen behind its peers in terms of number of cell therapies on the market and number of indications. Next-generation cell therapies like CAR-NKs and allogeneic CAR-Ts are coming into play as well. But the Swiss drug maker is looking to make its mark with a new autologous cell therapy technology that speeds manufacturing, and introduced early data on two of these candidates at the American Society of Hematology (ASH) annual meeting.
On 13 December, Novartis presented Phase I data at ASH for two autologous CAR-T therapy candidates, the CD19-targeting YTB323 in...






